Growth and survival of giant gourami juvenile immersed in different doses of recombinant growth hormone

Pertumbuhan dan kelangsungan hidup juvenil ikan gurami direndam dalam hormon pertumbuhan rekombinan dengan dosis berbeda

Alimuddin*1, Sumie Etoh2, Handika Gilang Pramana Putra1, Odang Carman1

1 Department of Aquaculture, Faculty of Fisheries and Marine Sciences, Bogor Agricultural University
   Bogor 16680 Indonesia
2 Department of Marine Biosciences, Tokyo University of Marine Science and Technology
   Minato, Tokyo 108-8477, Japan
*email: alimuddin_alsani@yahoo.com

ABSTRACT

This study was aimed at enhancing the growth of giant gourami Osphronemus goramy fry by immersion with recombinant giant gourami growth hormone (r-OgGH). Immersion with solution containing inclusion bodies with different doses of r-OgGH, 0 mg/L (control), 10 mg/L, 20 mg/L, and 30 mg/L was performed on weekly basis for the first three weeks of experimental period. Fish were reared for five weeks in glass aquaria at a stocking density of 7 fish/L, and fed with Artemia nauplii and blood worm twice a day ad libitum. The results showed that the average body weight of 30 mg/L r-OgGH treated fish (0.34 g) was 75% higher (p<0.05) than those of 10 mg/L (0.24 g) and control (0.19 g). The highest survival was obtained at 30 mg/L r-OgGH immersed fish (100%), followed by 20 mg/L (96%) and 10 mg/L treated fish (94%), and control (94%). The results indicate that immersion with recombinant growth hormone could be applied to enhance the growth and survival of giant gourami juvenile.

Keywords: recombinant protein, growth hormone, immersion, Osphronemus goramy

INTRODUCTION

Giant gourami Osphronemus goramy has the highest price compared to that of other freshwater species in Indonesia. Production of giant gourami is targeted to be 48,900 metric ton in 2014, or 27% higher than in 2009 (Ismanadji, 2010). The crucial problem to meet the target is giant gourami performs slow growth, where it spends about one year of rearing to reach its market size of 500 g. Hence, a technique to accelerate its growth is required. The application of growth stimulation technique using recombinant growth hormone (rGH) is considered to be an advantage approach.

Advances in recombinant DNA technology have offered a way to produce large amounts of teleostean growth hormones using bacteria Escherichia coli as a vector (Sekine et al., 1985; Sato et al., 1989; Sugimoto & Yokoo, 1991; Tsai et al., 1995; Promdonkoy et al., 2004; Funkenstein et al., 2005). Furthermore, administration of
recombinant fish growth hormone (rGH) has been reported to considerably increase the growth of finfish (Moriyama & Kawauuchi, 1990; Lin et al., 1995; Tsai et al., 1997; Ben-Atia et al., 1999; Promdonkoy et al., 2004; Funkenstein et al., 2005; Acosta et al., 2009) and shellfish (Xu et al., 2000; Moriyama & Kawauuchi, 2004; Santiesteban et al., 2010). Treatment of rGH can also enhance fish survival through increasing its resistance to disease (Sakai et al., 1997) and stress conditions such as salinity (reviewed by McCormick, 2001). The used of rGH may also increase the growth and survival of giant gourami.

There are three types of giant gourami juvenile usually offer as market size, namely the size of ‘kuku’ (about 3 cm in total body length/BL), ‘jempol’ (BL of ~4 cm), ‘silet’ (BL of ~6 cm), and ‘korek’ (BL of ~8 cm). Administration of rGH in larval stage is suggested to be considerably increasing the growth of giant gourami juvenile. Delivery of rGH into larval and juvenile of fish is generally conducted by immersion bath method (Moriyama & Kawauuchi, 1990; Moriyama et al., 2008; Acosta et al., 2009; Santiesteban et al., 2010). This research was aimed to stimulate the growth of giant gourami fry by administration of recombinant giant gourami growth hormone (r-OgGH) into 1-day after yolk egg absorbed larvae.

**MATERIALS AND METHODS**

**Construction of protein expression vector**

Signal peptide sequence of giant gourami growth hormone (Nugroho et al., 2008) was predicted using SignalP 3.0 software (http://www.cbs.dtu.dk/services/signalP). Predicted nucleotide sequence encoding mature growth hormone of giant gourami (OgGH) was amplified by PCR using a set primer of Og-mGH-F (5’-GGATCC CAG CCA ATC ACA GAC AGC CAG-3’) and Og-mGH-R (5’-GAATTCT CA TGA GAT GCA GTT AGC TTC TGG-3’), containing Bam HI and Eco RI recognition sites (underlined) respectively. Subsequently, the PCR products were purified and cloned into the pGEM-T Easy vector (Promega, Madison, USA). Bam HI/Eco RI-double digested OgGH cDNA fragment was then ligated into the corresponding sites of the expression vector pCold-I (Takara Bio Inc., Japan) driven by cspA promoter. The constructed plasmid was designated as pCold-I/OgGH (Alimuddin et al., 2010).

**Production of r-OgGH**

*Escherichia coli* BL21 (DE3) harboring pCold-I/OgGH was inoculated in 4 mL of 2×YT medium containing 100 µg/mL of ampicillin and was incubated overnight at 37 °C. Induction of protein synthesis was performed by adding 1 mM IPTG (isopropyl-b-D-thiogalactopyranoside) and subsequently incubated at 15 °C for 24 hours. The bacterial cells were harvested by centrifugation at 12,000 rpm for 1 min at 4 °C, then was resuspended in phosphate buffer saline (PBS) containing 0.1% Triton X-100, and was washed twice by the same solution. Bacterial cells was lysed by adding 500 µl lysozyme (10 mg/mL lysozyme in TE buffer) and was incubated at 37 °C for 20 min, or was sonicated six times for 30 s on ice. Inclusion bodies were collected by centrifugation at 12,000 rpm for 5 min, and the pellet was washed twice by 1 M NaCl containing 1% Triton X-100, and then was resuspended in PBS containing SDS and β-mercaptoethanol. Sample of inclusion bodies solution was heated at 100 °C for 10 min, and then was chilled on ice and was centrifuged briefly. An aliquot of 10 µL was analyzed by SDS-PAGE with 10% polyacrylamide gel, and protein was visualized using Coomassie Blue dye. The recombinant protein was stored at -80 °C until use.

**Immersion of recombinant growth hormone and fish rearing**

There are three series of immersion treatments due to concentration of r-OgGH, i.e. 10 mg/L, 20 mg/L, and 30 mg/L respectively, and one treatment without r-OgGH as the control. In amount of 50 fish
was used for each treatments including for the control treatment. The 50 fish of one day after first feeding were subjected to hyper osmotic shock of 3.5% NaCl for 2 min (this was obtained from our preliminary study), and subsequently immersed for 60 min in 200 mL of r-OgGH solution at different concentrations depend on the treatment and without r-OgGH as the control. Along with the hormone, 0.9% of NaCl and 0.01% of BSA were also added to the immersion solution. The treatment was performed in duplicate and was performed once weekly for three weeks.

Fish were reared for five weeks in 8 L of glass aquaria with water temperature of 27±1 °C, and fed with Artemia nauplii during the first week and blood worms for the next four weeks. Feeding was conducted twice a day ad libitum. Water quality was maintained by daily water replacement at a level of 50% for the first two weeks, and 80% for the remaining three weeks. Fish body weight was measured at seven days interval. Fish feeding response was observed in the 5th week.

**Statistical analysis**
Statistical analysis were performed by SPSS 16.0 software package. Differences in body weight and growth rate were determined by one-way ANOVA followed by Duncan’s test at a significance level of p=0.05. Survival and fish feeding response were descriptively described.

**RESULTS**

**Recombinant growth hormone production**
Inclusion bodies containing recombinant giant gourami growth hormone (r-OgGH) obtained from 100 mL of bacterial culture was about 390 mg in wet weight. Result of SDS-PAGE analysis (Fig. 1) showed that E. coli BL21 carrying pCold-1/OgGH expression vector could produce a relatively high level of r-OgGH in the size of about 21 kDa.

**Fish growth**
The changes of body weight of non-treated control and r-OgGH treated groups fish is shown in Fig. 2A. Significant increment in body weight of treated fish groups, especially those treated with 30 mg/L r-OgGH was initially observed on the third week of experimental period, and this consistently observed until the 3rd week of treatment. By the end of experiment, both 20 and 30 mg/L r-OgGH treated fish body weight showed 75% and 64% higher than the control (P<0.05), whereas no significant difference (P>0.05) was observed between fish treated with 10 was observed between fish treated with 10 mg/L r-OgGH (0.24 g) and those of control (0.19 g). Furthermore, the growth rate of 30 mg/L (2.86%/day) and 20 mg/L r-OgGH treated fish (2.63%/day) was comparable (P>0.05), and both were significantly higher (P<0.05) than those of 10 mg/L r-OgGH treated fish (2.14%/day) and the control (1.69%/day). Phenotype of 30 mg/L r-OgGH treated fish and those of control fish after five weeks rearing period was shown in Fig. 2B.

![Fig. 1. SDS-PAGE analysis of inclusion bodies containing recombinant giant gourami growth hormone (arrow head) separated in 10% SDS-PAGE gel. Lane 1: inclusion bodies from lysozyme-lysed bacterial cells. Lane 2: inclusion bodies from sonicated bacterial cells. pC: inclusion bodies from bacterial cells carrying pCold-1 empty. M: molecular weight marker.](image-url)
Fig. 2. Changes in body weight (g) of giant gourami fry in control (○–○), 10 mg/L (■–■), 20 mg/L (▲–▲), and 30 mg/L recombinant growth hormone-immersed groups fish (●–●) for 5 weeks rearing period (a). Fish (n=50) were immersed in the hormone solution for 60 min on weekly basis for the first three of five weeks of experimental period. The photograph shows the phenotype of non-treated control and 30 mg/L recombinant growth hormone-treated groups of fish after five weeks of rearing period in 8-l aquaria (b).

Table 1. Body weight (g), growth (%) and survival (%) rates of giant gourami fry in control and recombinant growth hormone-immersed fish at different doses

<table>
<thead>
<tr>
<th>r-OgGH dose treatments (mg/L)</th>
<th>Body weight (g)</th>
<th>Growth rate (%/day)</th>
<th>Survival rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (control)</td>
<td>0.19±0.001&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.69&lt;sup&gt;a&lt;/sup&gt;</td>
<td>94±2.0</td>
</tr>
<tr>
<td>10</td>
<td>0.24±0.023&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.14&lt;sup&gt;a&lt;/sup&gt;</td>
<td>94±2.0</td>
</tr>
<tr>
<td>20</td>
<td>0.32±0.012&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2.64&lt;sup&gt;b&lt;/sup&gt;</td>
<td>96±4.0</td>
</tr>
<tr>
<td>30</td>
<td>0.34±0.004&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2.86&lt;sup&gt;b&lt;/sup&gt;</td>
<td>100±0.0</td>
</tr>
</tbody>
</table>

The body weight and survival of fish are given as mean ±SE of duplicated treatments. r-OgGH is recombinant giant gourami Osphronemus goramy growth hormone. Different superscript letters in the same column indicate significant differences (P<0.05).

Fig. 3. Different responses to live food (blood worm) of giant gourami with non-treated control (A), 10 mg/L (B), 20 mg/L (C), and 30 mg/L recombinant growth hormone-treated (D). Photographs were taken on the last week of rearing period.

**Fish feeding response**

Visual observation on fish feeding behavior showed that treatment of rGH in giant gourami fry could increase the fish feeding response. This response was initially observed on the second week and continuously shown for the remaining weeks of experimental period (Fig. 3). Figure 3 also shows that the number of fish which response to feeding was found to be higher as the doses of r-OgGH treatment increases.

**DISCUSSION**

It is well known that the growth of giant gourami is relatively slower than other freshwater aquaculture species. Several manipulation techniques such as selection have been applied as an effort to improve fish growth. However, to obtain a significant genetic gain this technique is labor intensive and time-consuming. Therefore, another technique such as the application of recombinant growth hormone can be applied as an alternative way with a minimum cost and time. This experiment showed that application of recombinant growth hormone r-OgGH for three consecutive weeks with at dose of 30 mg/L and 20 mg/L resulted in significant increase (p<0.05) of 75% and
64% growth rate, respectively, when compared to the control. Furthermore, the growth was still higher at the end of experiment (five weeks) even the treatment had been stopped in the third week (Fig. 2A). Similar results were also reported in salmonid (Moriyama & Kawauchi, 1990), striped bass, channel catfish, grass carp (Sonnenschein, 2001), abalone (Moriyama & Kawauchi, 2004), Nile tilapia, goldfish, and common carp (Acosta et al., 2009).

Inclusion bodies obtained from 100 mL of bacterial culture was about 390 mg in wet weight. With the dose of 30 mg/L and 20 mg/L, three times immersion and 250 fish can be immersed in 1 L water, so that the total numbers of fish that can be treated using 390 mg recombinant protein were about 1,080 and 1,600 fish, respectively. The number of the treated fish per immersion can be increased if its density during the treatment is raised to more than 50 fish per 200 mL, thus improving the efficiency of the use of rGH. Increasing the number of treated fish however may result in lower growth acceleration, therefore an optimum fish density for an efficient recombinant growth hormone immersion treatment still requires further investigation.

Indonesian farmers commonly perform size grading for giant gourami seed production where the price is determined based on total body length, i.e. ‘kuku’ (2–3 cm, IDR 150–250 in price), ‘jempol’ (3–4 cm, IDR 500–750), and ‘silet’ (5–6 cm, IDR 1,500–2,000). When this grading is applied to the result of this experiment at the end of the rearing period, it is found that the size of fry obtained from the treatment with a dose of 30 mg/L r-OgGH was mostly categorized into ‘jempol’ size, while non-treated control was mostly ‘kuku’ size. Thus, the administration of rGH not only shorten the time required to obtain fry with ‘jempol’ size, but also improves the farmers income as the price of this size of fry is 2 times higher than the ‘kuku’ size.

The immersion method has been developed in various fish species, fish stages (larvae, fry, or juvenile), concentrations and GH sources (fish and mammalian origin), purities (purified or crude protein), frequencies and intervals (once to several times immersion, and once to thrice weekly), methods and periods of fish rearing. Level of growth acceleration is also varied, such as 63% in grass carp, 45% in channel catfish, 35.5% in striped bass and 20% in freshwater prawn using bovine somatotropin (Sonnenschein, 2001), 20% in abalone using salmon GH (Moriyama & Kawauchi 2004), 100% in tilapia juvenile using tilapia GH (Acosta et al., 2009) and 42.4% in Pacific white shrimp using tilapia GH (Santiesteban et al., 2010). In our study, immersion was performed using crude protein as inclusion bodies containing r-OgGH resulted a significant growth enhancement of giant gourami larvae approximately 75% at the dose treatment of 30 mg/L.

Survival rate of fish treated by 30 mg/L r-OgGH was higher compared to that of other dose treatments and non-treated control (Table 1). Water quality was equally maintained among treatments, and no pathogen infection was visually observed during experiment. Thus, it is more likely that increasing of survival rate is due to response of r-OgGH treatment. Furthermore, increasing in survival of the r-OgGH treated fish perhaps as a result of an improved resistance of fish to hyperosmotic treatment. In fact, administration of ovine GH increase survival rate of amago salmon Oncorhynchus rhodurus in 32% seawater (Miwa & Inui, 1985). This effect is due to the capacity of GH to increase the number and size of gill chloride cells, Na⁺,K⁺-ATPase, and the Na⁺, K⁺, 2Cl⁻ cotransporter (NKCC), ion transporters involved in salt secretion (McCormick, 2001), and some of the actions of GH are through insulin-like growth factor I (Sakamoto & McCormick, 2006). The same actions of r-OgGH may also involve in giant gourami. In addition, administration of rGH enhances resistance of rainbow trout against bacterial pathogen Vibrio anguillarum (Sakai et al., 1997). This effect is through stimulation of innate immune system (Sakai et al., 1997; Acosta et al., 2008). A similar stimulation effect of r-OgGH may also exist against bacterial pathogen infection, and this remains to study in future.

Growth hormone treatment increased
appetite of giant gourami juvenile. This was clearly seen in fish treated with r-OgGH at a dose of 30 mg/L (Fig. 3). Similar response had also been reported in channel catfish treated by recombinant bovine growth hormone (Wilson et al., 1988) and goldfish treated with recombinant giant catfish growth hormone (Promdonkoy et al., 2004). The appetite stimulation that affects feed consumption had been suggested as a mainly factor in increase of channel catfish growth following rGH treatment (Wilson et al., 1988). This maybe also takes place in growth enhancement of r-OgGH-treated giant gourami juvenile. In fact, growth rate of 30 mg/L and 20 mg/L r-OgGH treated fish was higher than those of 10 mg/L r-OgGH treated fish and non-treated fish (Table 1).

In conclusion, we have demonstrated the growth- and survival-promoting effects of r-OgGH on giant gourami juvenile following immersion. It suggested that the rearing period of giant gourami to harvesting period can be shorten, and survival of larvae can also be improved. To our knowledge, this is the first study that has achieved the growth enhancement of giant gourami using recombinant growth hormone.

ACKNOWLEDGEMENT

This study was partly supported by Directorate General of Higher Education, the Ministerial of Education, Indonesia through a grant of “Hibah Kompetensi” No.: 219/SP2H/PP/DP2M/V/2009, to Alimuddin.

REFERENCES


